Asymmetric dimethylarginine and hemodynamic regulation in middle-aged men

Metabolism: Clinical and Experimental

Volumn 55, Issue 6, 2006, Pages 771-777

  Päivä, Hannu ^a   Laakso, Juha ^b   Kähönen, Mika ^a,c   Turjanmaa, Väinö ^a,c   Kööbi, Tiit ^a,c   Majahalme, Silja ^d   Lehtimäki, Terho ^a,c   Ruokonen, Inkeri ^e   Laaksonen, Reijo ^a,e  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d Appleton Heart Institute   (United States)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARGININE DERIVATIVE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; DIMETHYLARGININE; DRUG DERIVATIVE; NITRIC OXIDE SYNTHASE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEART OUTPUT; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONITORING; PRIORITY JOURNAL; PULSE WAVE; TANDEM MASS SPECTROMETRY; VASCULAR RESISTANCE; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; DRUG ANTAGONISM; FINLAND; MASS SPECTROMETRY; MIDDLE AGED;

ARGININE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FINLAND; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MALE; MASS SPECTROMETRY; MIDDLE AGED; NITRATES; NITRIC OXIDE SYNTHASE;

EID: 33745766153     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.01.014     Document Type: Article

References (39)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
2. Leiper J., and Vallance P. Biological significance of endogenous methylargines that inhibit nitric oxide synthase. Cardiovasc Res 43 (1999) 542-548
3. Miyazaki H., Matsuoka H., Cooke J.P., et al. Endogenous nitric oxide synthase inhibitor, a novel marker of atherosclerosis. Circulation 99 (1999) 1141-1146
4. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
5. Delles C., Schneider M.P., John S., et al. Angiotensin converting enzyme inhibition and angiotensin II AT 1-receptor blockade reduce the levels of asymmetrical N(g), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 15 (2002) 590-593
6. Päivä H., Lehtimäki T., Laakso J., et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 52 (2003) 303-307
7. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
8. Päivä H., Laakso J., Laine H., et al. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 40 (2002) 1241-1247
9. Achan V., Broadhead M., Malaki M., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 (2003) 1455-1459
10. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252 [electronic publication 2003 Dec 01]
11. O'Brien E., Mee F., Atkins N., et al. Accuracy of the SpaceLabs 90207, Novacor Diasys 200, Del Mar Avionics Pressurometer IV and Takeda TM-2420 ambulatory systems according to British and American criteria. J Hypertens 9 (1991) S332-S333
12. O'Brien E., O'Malley K., Mee F., et al. Ambulatory blood pressure measurements in the diagnosis and management of hypertension. J Hum Hypertens 5 (1991) 23-30
13. Devereux R.B., James G.D., and Pickering T.G. What is normal blood pressure? Comparison of ambulatory blood pressure level and variability in patients with normal or abnormal left ventricular geometry. Am J Hypertens 6 (1993) S211-S215
14. Imholz B.P., van Montfrans A., Settels J.J., et al. Continuous non-invasive blood pressure monitoring: reliability of Finapres device during the Valsalva manouver. Cardiovasc Res 22 (1988) 390-397
15. Imholz B.P., Settels J.J., van der Meiracker A.H., et al. Non-invasive continuous finger blood pressure measurement during orthostatic stress compared to intra-arterial pressure. Cardiovasc Res 24 (1990) 214-221
16. Kööbi T., Kaukinen S., Ahola T., et al. Non-invasive measurement of cardiac output: whole-body impedance cardiography in simultaneous comparison with thermodilution and direct oxygen Fick methods. Intensive Care Med 23 (1997) 1132-1137
17. Kööbi T., Kaukinen S., Turjanmaa V.M., et al. Whole-body impedance cardiography in the measurement of cardiac output. Crit Care Med 25 (1997) 779-785
18. Tishchenko M.I. Estimation of the stroke volume by integral rheogram of the human body. Sechenov Physiol 59 (1973) 1216-1224
19. Chemla D., Hebert J.L., Coirault C., et al. Total arterial compliance estimated by stroke volume-to-aortic pulse pressure ratio in humans. Am J Physiol 274 (1998) H500-H505
20. de Simone G., Roman M.J., Daniels S.R., et al. Age-related changes in total arterial capacitance from birth to maturity in a normotensive population. Hypertension 29 (1997) 1213-1217
21. Kööbi T., Kähönen M., Iivanainen T., et al. Simultaneous non-invasive assessment of arterial stiffness and haemodynamics-a validation study. Clin Physiol Funct Imaging 23 (2003) 31-36
22. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
23. Vishwanathan K., Tackett R.L., Stewart J.T., et al. Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 748 (2000) 157-166
24. Kielstein J.T., Impraim B., Simmel S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-177
25. Shepherd J.T. Franz Volhard Lecture. Increased systemic vascular resistance and primary hypertension: the expanding complexity. J Hypertens Suppl 8 (1990) S15-S27 [Review]
26. Palmer R.M.J., Ferrige A.G., and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526
27. Böger R.H., Lentz S.R., Bode-Böger S.M., et al. Elevation of asymmetrical dimethylarginine may medicate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci Lond 100 (2001) 161-167
28. Dominiczak A.F., and Bohr D.F. Nitric oxide and its putative role in hypertension. Hypertension 25 (1995) 1202-1211
29. Cockcroft J.R., Chowienczyk P.J., Benjamin N., et al. Preserved endothelium-dependent vasodilation in patients with essential hypertension. N Engl J Med 330 (1994) 1036-1040
30. Laurent S., Lacolley P., Brunel P., et al. Flow-dependent vasodilation of brachial artery in essential hypertension. Am J Physiol 258 (1990) H1004-H1011
31. Forte P., Copland M., Smith L.M., et al. Basal nitric oxide synthesis in essential hypertension. Lancet 349 (1997) 837-842
32. Bode-Böger S.M., Böger R.H., Kielstein J.T., et al. Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension. J Investig Med 48 (2000) 125-132
33. National Academy of Sciences Committee on Nitrate and Alternative Curing Agents in Food. The health effects of nitrate, nitrite and N-nitroso compounds (1981), National Academy Press, Washington (DC)
34. Böger R.H., Sydow K., Borlak J., et al. LDL cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87 (2000) 99-105
35. Valkonen V.P., Päivä H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
36. Valkonen V.P., Tuomainen T.P., and Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med Suppl 1 (2005) 45-48
37. Vallance P., Leone A., Calver A., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
38. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10 (1999) 594-600
39. Ito A., Egashira K., Narishige T., et al. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J 66 (2002) 811-815